银僵Ⅱ号治疗黄色瘤型坏死性淋巴结炎的效应机制研究  

Study on the mechanism of Yinjiang Ⅱ in the treatment of xanthoma necrotizing lymphadenitis

作　　者：傅良杰[1] 黄子慧[1] 钮晓红[1] 靳汝辉[1] 丁继果[1] FU Liangjie;HUANG Zihui;NIU Xiaohong;JIN Ruhui;DING Jiguo(Integrated Traditional Chinese and Western Medicine Hospital of Nanjing City, Nanjing 210014, Jiangsu, China)

机构地区：[1]江苏省南京市中西医结合医院

出　　处：《现代中西医结合杂志》2019年第30期3318-3321,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：南京市医学科技发展资金资助项目(YKK16212)

摘　　要：目的研究银僵Ⅱ号治疗黄色瘤型坏死性淋巴结炎的效应机制,为黄色瘤型坏死性淋巴结炎患者提供更有效的治疗方案。方法采用随机数字表法将108例黄色瘤型坏死性淋巴结炎患者随机分为对照1组、对照2组和观察组,每组36例,对照1组患者予以泼尼松治疗,对照2组患者予以银僵汤治疗,观察组患者予以银僵Ⅱ号治疗,3组均治疗12 d。比较3组的临床疗效、红细胞沉降率(ESR)、血清C反应蛋白(CRP)水平、外周血T淋巴细胞亚群CD4^+水平及CD4^+/CD8^+比值,统计3组不良反应发生情况。结果对照1组、对照2组和观察组总有效率分别为66.7%(24/36)、75.0%(27/36)和97.2%(35/36),观察组总有效率明显高于对照1组和对照2组(P均<0.05),对照1组与对照2组总有效率比较差异无统计学意义(P>0.05);3组治疗后ESR、CRP水平均明显低于治疗前(P均<0.05),且观察组均明显低于对照1组和对照2组(P均<0.05),对照2组均明显低于对照1组(P均<0.05);3组治疗后CD4^+、CD4^+/CD8^+均明显高于治疗前(P均<0.05),且观察组均明显高于对照1组和对照2组(P均<0.05),对照2组均明显高于对照1组(P均<0.05)。3组患者均未见明显不良反应。结论银僵Ⅱ号治疗黄色瘤型坏死性淋巴结炎疗效优于银僵汤和泼尼松,可明显减轻机体炎症反应,增强免疫功能,且安全。Objective It is to study the mechanism of Yinjiang Ⅱ in the treatment of xanthoma necrotizing lymphadenitis, in order to provide a more effective treatment regimen for patients with xanthoma necrotizing lymphadenitis. Methods A total of 108 patients with xanthoma necrotizing lymphadenitis were randomly divided into control group I(n=36), control group Ⅱ(n=36) and observation group(n=36) according to the random number table method. The control group I was treated with prednisone, the control group Ⅱ was treated with Yinjiang decoction, and the observation group was treated with Yinjiang Ⅱ. All the groups were treated for 12 days. The clinical efficacy, erythrocyte sedimentation rate(ESR), the level of serum C-reactive protein(CRP), the level of peripheral blood T lymphocyte subsets CD4^+ and CD4^+/CD8^+ ratio were compared among the three groups, and the occurrence of side effects were recorded. Results The total effective rates of control group Ⅰ, control group Ⅱ and observation group were 66.7%(24/36), 75.0%(27/36) and 97.2%(35/36), respectively. The total effective rates of the observation group was significantly higher than that of the other two groups(P<0.05), while there was no significant difference in the total effective rate between the control group Ⅰ and the control group Ⅱ(P>0.05). After treatment, the levels of ESR and CRP in the three groups were significantly lower than those before treatment(P<0.05), the levels of ESR and CRP in the observation group were significantly lower than those in control group Ⅰ and control group Ⅱ(P<0.05), and the levels of ESR and CRP in control group Ⅱ were significantly lower than those in control group Ⅰ(P<0.05). After treatment, the levels of CD4^+, CD4^+/CD8^+ in the three groups were significantly higher than those before treatment(P<0.05), and the levels of CD4^+, CD4^+/CD8^+ in in the observation group were significantly higher than those in control group Ⅰ and control group Ⅱ(P<0.05), and the levels of CD4^+, CD4^+/CD8^+ in control gr

关 键 词：银僵Ⅱ号 黄色瘤型 坏死性淋巴结炎 银僵汤 

分 类 号：R632.6[医药卫生—外科学]